FIGURE 6.

Systemic delivery of therapeutic MNVs reduce tumor burden in vivo. (A) An orthotopic HCC model was established by intrahepatic injection of SNU449 cells stably transfected to express luciferase. Nine days after implantation, 2 × 10¹¹ nontarget control miRNA loaded MNVs (control MNVs) or miR-126-3p loaded MNVs (tMNVs) were administered by tail vein injection every 2 days for a total of 5 doses. NK cells (2 × 10⁶) were adoptively transferred by tail vein injection on days 3 and 7 postinitiation of treatment with MNV. (B-C) Tumor burden was monitored by IVIS imaging. (D) The gross appearance of tumors harvested at the study endpoint showed a reduction in tumor formation. The values are expressed as the mean and SD (n = 5 mice per group). *p < 0.05. Abbreviations: IVIS, In Vivo Imaging System; MNVs, milk-derived nanovesicles; NK cells, natural killer cells; tMNVs, therapeutic MNVs.